Identification of a nonameric H-2K(k)-restricted CD8+ cytotoxic T lymphocyte epitope on the Plasmodium falciparum circumsporozoite protein
Article
Malik, A, Houghten, R, Corradin, G et al. (1995). Identification of a nonameric H-2K(k)-restricted CD8+ cytotoxic T lymphocyte epitope on the Plasmodium falciparum circumsporozoite protein
. INFECTION AND IMMUNITY, 63(5), 1955-1959. 10.1128/iai.63.5.1955-1959.1995
Malik, A, Houghten, R, Corradin, G et al. (1995). Identification of a nonameric H-2K(k)-restricted CD8+ cytotoxic T lymphocyte epitope on the Plasmodium falciparum circumsporozoite protein
. INFECTION AND IMMUNITY, 63(5), 1955-1959. 10.1128/iai.63.5.1955-1959.1995
Class I-restricted CD8+ cytotoxic T lymphocytes (CTL) against the circumsporozoite protein (CSP) protect mice against the rodent malaria parasite, Plasmodium yoelii, and vaccines designed to produce protective CTL against the P. falciparum CSP (PfCSP) are under development. Humans and B10.BR (H-2(k)) mice have been shown to have CD8+ CTL activity against a 23- amino-acid region of the PfCSP (residues 368 to 390 from the PfCSP 7G8 sequence) that is too long to bind directly to class I major histocompatibility complex molecules. To identify within this 23-amino-acid peptide a shorter peptide that binds to an H-2(k) class I major histocompatibility molecule, a primarily CD8+ (97.8%) T-cell line (PfCSP TCL.1) was produced by immunizing B10.BR mice with recombinant vaccinia virus expressing the PfCSP and stimulating in vitro spleen cells from these immunized mice with L cells transfected with the PfCSP gene (LPF cells). PfCSP TCL.1 lysed LPF cells and L cells pulsed with peptide PfCSP 7G8 368- 390. When 15 overlapping nonamer peptides spanning the 368 to 390 sequence were tested, only one peptide, PfCSP 7G8 375-383 (Y E N D I E K K I), which includes an H-2K(k)-binding motif, E at amino acid residue 2, and I at residue 9, sensitized targets for lysis by PfCSP TCL.1. Furthermore, a 103- to 104-fold lower concentration of the nonamer than that of the 23-amino- acid peptide was required to sensitize target cells for lysis by PfCSP TCL.1. Presentation by H-2K(k) was demonstrated by using 3T3 fibroblast cells transfected with the murine H-2K(k) or H-2D(k) genes, and only the H-2K(k) transfectants were lysed by PfCSP TCL.1 after incubation with peptide PfCSP 7G8 375-383. Binding to H-2K(k) was confirmed by competitive inhibition of binding of labelled peptides to affinity-purified K(k) molecules. Substitution of the anchor amino acid residue, E, at position 2 with A dramatically reduced binding to K(k) and eliminated the capacity of the peptide to sensitize target cells for killing. Variation of non-anchor residues did not markedly reduce binding to K(k) but in some cases eliminated the capacity of the peptide to sensitize targets for cytolysis by PfCSP TCL.1, presumably by eliminating T-cell receptor-binding sites. These data suggest that similar studies with human T cells will be required for optimal development of peptide-based vaccines designed to produce protective class I- restricted CD8+ CTL against the PfCSP in humans.
